Common GI Side Effects Reported with Darolutamide
Darolutamide, used to treat non-metastatic castration-resistant prostate cancer, frequently causes gastrointestinal issues in clinical trials. Nausea affects about 20% of patients, vomiting around 8%, and diarrhea 20%. Decreased appetite occurs in 11-13% of cases, while constipation and abdominal pain each impact roughly 5-6%.[1][2]
How Darolutamide Causes These Effects
As an androgen receptor inhibitor, darolutamide disrupts hormone signaling that can influence gut motility and secretion. It may slow gastric emptying (leading to nausea and constipation) or irritate the GI mucosa (causing diarrhea or pain). These stem from its off-target effects on smooth muscle and inflammation pathways, though exact mechanisms aren't fully detailed in labeling.[1][3]
Frequency and Severity in Studies
In the ARAMIS trial (2,919 patients), GI adverse events were mostly mild to moderate:
- Diarrhea: 20.3% (darolutamide) vs. 8.6% (placebo).
- Nausea: 20.0% vs. 10.0%.
- Serious GI events were rare (<2%), with no treatment discontinuations due to severe vomiting.[2]
Real-world data aligns, with nausea resolving in most without intervention.
Managing GI Side Effects
Take darolutamide with food to reduce nausea. For diarrhea, use loperamide; for constipation, increase fiber and hydration. Antiemetics like ondansetron help nausea. Dose adjustments aren't standard, but monitor electrolytes if diarrhea persists.[1][3] Consult a doctor before starting supplements like probiotics.
Rare or Serious GI Risks
Severe cases include grade 3-4 diarrhea (2%) or colitis (<1%), potentially linked to immune modulation. GI bleeding or perforation is possible but uncommon (<0.5%). Avoid in patients with active GI ulcers.[1]
Comparison to Similar Drugs
| Drug | Nausea | Diarrhea | Constipation |
|------|--------|----------|--------------|
| Darolutamide | 20% | 20% | 5% |
| Enzalutamide | 11% | 22% | 7% |
| Apalutamide | 18% | 21% | 14% |
Darolutamide shows lower CNS effects but similar GI profile to other AR inhibitors.[2][4]
Sources
[1]: Darolutamide Prescribing Information (Nubeqa, Bayer)
[2]: ARAMIS Trial (NEJM, 2019)
[3]: Medscape Darolutamide Side Effects
[4]: DrugPatentWatch.com - Androgen Receptor Inhibitors Comparison